Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 1.345
-3.93 %
$ 196 M
Market Cap
-3.64
P/E
CASH FLOW STATEMENT
-22.9 M
OPERATING CASH FLOW
-23.1 M
INVESTING CASH FLOW
29.1 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Biodesix, Inc.
| Net Income | -52.1 M |
| Depreciation & Amortization | 5.51 M |
| Capital Expenditures | -23.1 M |
| Stock-Based Compensation | 5.37 M |
| Change in Working Capital | 11.3 M |
| Others | 22.4 M |
| Free Cash Flow | -45.9 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (52.1) | (65.4) | (43.2) | (31.4) | (30.7) | (26.2) |
| Depreciation & Amortization | 5.5 | 5.8 | 3.2 | 2.9 | 2.8 | 1.7 |
| Deferred Income Tax | 0 | 0 | (2.1) | 1.6 | 2.4 | 47 K |
| Stock Based Compensation | 5.4 | 6.0 | 4.9 | 3.7 | 0.2 | 0.1 |
| Other Operating Activities | 7.1 | 13.0 | 4.3 | 6.6 | 5.3 | 6.3 |
| Change in Working Capital | 11.3 | (4.3) | 4.6 | (4.8) | (1.6) | 0.3 |
| Cash From Operations | (22.9) | (45.0) | (28.2) | (21.4) | (21.7) | (17.7) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (23.1) | (3.5) | (2.5) | (2.2) | (1.4) | (0.6) |
| Other Items | 0 | 0 | 0 | (0.8) | (0.5) | 0 |
| Cash From Investing Activities | (23.1) | (3.5) | (2.5) | (2.9) | (1.9) | (0.6) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 10.0 | 16.5 | (15.3) | 16.0 | 13.0 | (12.6) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (8.9) | (17.2) | 0.3 | (6.9) | 19.9 | 31.7 |
| Cash From Financing Activities | 29.1 | 58.9 | 1.3 | 81.1 | 23.0 | 19.0 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (16.8) | 10.4 | (29.5) | 56.8 | (0.6) | 0.7 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (45.9) | (48.5) | (30.8) | (23.5) | (23.1) | (18.3) |